Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes

Medical Science Monitor

Volumn 14, Issue 11, 2008, Pages

  Zhou, Jian ^a   Jia, Weiping ^a,b   Bao, Yuqian ^a   Ma, Xiaojing ^a   Lu, Wei ^a   Li, Huating ^a   Hu, Cheng ^a   Xiang, Kunsan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Continuous glucose monitoring; Glycemic variability; HbA 1c; Hypoglycemia; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RISK FACTOR;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN; MALE;

EID: 55549133977     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rathmann W, Giani G: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004; 27: 2568-69
2. Tripathi BK, Srivastava AK: Diabetes mellitus: complications and therapeutics. Med Sci Monit, 2006; 12(12): RA130-47
3. Stratton IM, Adler AI, Neil HA et al: Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br Med J, 2000; 321: 405-12
4. Hirsch IB, Brownlee M: Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications, 2005; 19: 178-81
5. Del Prato S: In search of normoglycaemia in diabetes: controlling postprandial glucose. Int J Obes Relat Metab Disord, 2002; 26: S9-17
6. Guerci B: Asymptomatic glycemic instability: how to measure it and which clinical applications? Diabetes Metab, 2003; 29: 179-88
7. Selam JL: How to measure glycemic instability? Diabetes Metab, 2000; 26: 148-51
8. Klonoff DC: A review of continuous glucose monitoring technology, Diabetes Technol Ther, 2005; 7: 770-75
9. st century diabetes therapy, Diabetes care, 2005; 28: 1231-39
10. Bode BW, Steed RD, Schleusener DS, Strange P: Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. Endocr Pract, 2005; 11: 157-64
11. Alemzadeh R, Palma-Sisto P, Parton EA, Holzum MK: Continuous subcutaneous insulin infusion and multiple dose of insulin regimen display similar patterns of blood glucose excursions in pediatric type 1 diabetes. Diabetes Technol Ther, 2005; 7: 587-96
12. Colette C, Ginet C, Boegner C et al: Dichotomous responses of inter and postprandial hyperglycaemia to short-term calorie restriction in patients with type 2 diabetes. Eur J Clin Invest, 2005; 35: 259-64
13. Nathan DM, Buse JB, Davidson MB et al: Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2006; 49: 1711-21
14. American Diabetes Association: Standards of medical care in diabetes. Diabetes care, 2005; 28: S4-36
15. The expert committee on the diagnosis and classification of diabetes mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 2003; 26: 3160-67
16. Mastrototaro J: The MiniMed continuous glucose monitoring system (CGMS). J Pediatr Endocrinol Metab, 1999; 12: 751-78
17. American Diabetes Association: Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care, 2005; 28: 1245-49
18. Kubiak T, Hermanns N, Schreckling HJ et al: Assessment of hypoglycaemia awareness using continuous glucose monitoring. Diabet Med, 2004; 21: 487-90
19. Service FJ, Molnar GD, Rosevear JW et al: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes, 1970; 19: 644-55
20. Monnier L, Mas E, Ginet C et al: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA, 2006; 295: 1681-87
21. Molnar GD, Taylor WF, Ho MM: Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia, 1972; 8: 342-48
22. McCall AL, Cox DJ, Crean J et al: A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther, 2006; 8: 644-53
23. Hirsch IB: Glycemic variability: it's not just about A1C anymore! Diabetes Technol Ther, 2005; 7: 780-83
24. The Diabetes Control and Complication Trial Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes, 1995; 44: 968-83
25. Muggeo M, Zoppini G, Bonora E et al: Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care, 2000; 23: 45-50
26. Zhou J, Jia WP, Yu M et al: The reference values of glycemic parameters for continuous glucose monitoring and its clinical application. Zhonghua Nei Ke Za Zhi, 2007; 46: 189-92
27. Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care, 2007; 30: 263-69
28. Maia FF, Araujo LR: Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Diabetes Res Clin Pract, 2007; 75: 30-34
29. Rubio-Guerra AF, Vargas-Robles H, Ayala GV, Escalante-Acosta BA: Correlation between circulating adhesion molecule levels and albuminuria in type 2 diabetic normotensive patients. Med Sci Monit. 2007; 13(8): CR349-52
30. Bonora E: Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl, 2002; (129): 5-11
31. Milagros Rocha M, Victor VM: Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone. Med Sci Monit, 2007;13(7): RA132-45
32. Galic E, Vrtovec M, Bozikov V et al: The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. Med Sci Monit, 2005; 11(12): PI87-92
33. Ceriello A, Lush CW, Darsow T et al: Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. Diabetes Metab Res Rev, 2008; 24(2): 103-8
34. Monnier L, Colette C, Rabasa-Lhoret R et al: Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care, 2002; 25: 737-41
35. Wentholt IM, Hart AA, Hoekstra JB, Devries JH: Relationship between interstitial and blood glucose in type 1 diabetes patients: delay and the push-pull phenomenon revisited. Diabetes Technol Ther, 2007; 9: 169-75
36. Daenen S, Sola A, Larger E et al: Use of the CGMS to assess the optimal time to measurepostprandial glucose [abstract]. Diabetes, 2006; 55: A17
37. Ben-Haroush A, Yogev Y, Chen R et al: The postprandial glucose profile in the diabetic pregnancy. Am J Obstet Gynecol, 2004; 191: 576-81
38. American Diabetes Association: Postprandial blood glucose. Diabetes Care, 2001; 24: 775-78
39. Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care, 2003; 26: 1902-12
40. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998; 352: 837-53